Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Next Previous
Trial Profile

A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Binimetinib (Primary) ; Crizotinib (Primary) ; Darovasertib (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Skin cancer; Solid tumours; Uveal melanoma
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept; Registrational; Therapeutic Use
  • Sponsors IDEAYA Biosciences

    • Most Recent Events

    • 24 Oct 2023 Results (At data cut-off : 08 Mar2023; n=68) assessing ctDNA reduction and clinical efficacy of the darovasertib plus crizotinib combination in metastatic uveal melanoma, presented at the 48th European Society for Medical Oncology Congress.
    • 17 Oct 2023 Results presented in the IDEAYA Biosciences Media Release.
    • 10 Aug 2023 According to an IDEAYA Biosciences media release, data from this trial will be presented as oral presentation at ESMO 2023 scheduled for Monday, October 23, 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top